Cover Image

Safety and efficacy of ruxolitinib cream for the treatment of vitiligo: A randomised controlled trial secondary analysis at 3 years

Saved in:

Bibliographic Details
Main Authors:	John E. Harris (Author), Amit G. Pandya (Author), Mark Lebwohl (Author), Iltefat H. Hamzavi (Author), Pearl Grimes (Author), Alice B. Gottlieb (Author), Howard L. Sofen (Author), Angela Y. Moore (Author), Mingyue Wang (Author), Deanna Kornacki (Author), Kathleen Butler (Author), David Rosmarin (Author)
Format:	Book
Published:	Wiley, 2024-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Baseline Levels of Circulating Inflammatory Biomarkers Stratify Patients with Vitiligo Who Significantly Repigment after Treatment with Ruxolitinib Cream
by: Michael D. Howell, et al.
Published: (2023)

Psychometric Evaluation of the Facial and Total Vitiligo Area Scoring Index Instruments in the TRuE-V Phase 3 Studies
by: Kristen Bibeau, et al.
Published: (2024)

Assessing Participants' Experiences with Vitiligo from Patient Interviews
by: Amit G. Pandya, et al.
Published: (2024)

Ruxolitinib cream for the treatment of cutaneous sarcoidosis
by: Jeffrey S. Smith, MD, PhD, et al.
Published: (2023)

Ruxolitinib cream for the treatment of granuloma annulare
by: Austin J. Piontkowski, BS, et al.
Published: (2024)

Treatment of cutaneous lupus with topical ruxolitinib cream
by: Jonathan J. Park, PhD, et al.
Published: (2022)

Topical steroid withdrawal treated with ruxolitinib cream
by: Moira Shea, BS, et al.
Published: (2024)

Efficacy and Safety of Ruxolitinib Cream in Atopic Dermatitis Based on Previous Medication History
by: Andrew Blauvelt, et al.
Published: (2024)

Improvement of necrobiosis lipoidica with topical ruxolitinib cream after prior nonresponse to compounded topical tofacitinib cream
by: Shannon Nugent, BS, et al.
Published: (2022)

Treatment of granulomatous perioral dermatitis with 1.5% topical ruxolitinib cream
by: Sophia S. Tran, BS, et al.
Published: (2024)

Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
by: Paul Smith, et al.
Published: (2021)

Recalcitrant Hailey-Hailey disease successfully treated with topical ruxolitinib cream and dupilumab
by: Juna Khang, BA, et al.
Published: (2023)

Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies
by: Eric L. Simpson, et al.
Published: (2024)

Report of novel treatment of segmental vitiligo using combined microneedling and topical ruxolitinib
by: Rama Abdin, et al.
Published: (2024)

Satisfaction with Control of Mild to Moderate Atopic Dermatitis with Ruxolitinib Cream: US Physician and Patient Perspectives
by: Lawrence F. Eichenfield, et al.
Published: (2024)

The use of topical ruxolitinib 1.5% cream in frontal fibrosing alopecia: A case report
by: Deesha Desai, BS, et al.
Published: (2024)

Association of myalgias with compounded topical Janus kinase inhibitor use in vitiligo
by: Shanthi Narla, MD, et al.
Published: (2020)

Genital vitiligo following use of imiquimod 5% cream
by: Ruzhi Zhang, et al.
Published: (2011)

Ruxolitinib, a JAK1/2 Inhibitor as Treatment for Paraneoplastic Pemphigus: A Case Report
by: Birao Fan, et al.
Published: (2022)

T-cell/histiocyte-rich large B-cell lymphoma in a 27-year-old with hidradenitis suppurativa, psoriasis, and vitiligo: Implications for screening
by: Gautham Vellaichamy, MD, et al.
Published: (2020)

Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
by: Manduzio P
Published: (2017)

Vitiligo-Like Depigmentation following Treatment with Imiquimod 5% Cream for Condylomata Acuminata
by: Maram Alatabani, et al.
Published: (2021)

Real-World Treatment Patterns in Patients with Vitiligo in the United States
by: David Rosmarin, et al.
Published: (2023)

Topical ruxolitinib for the treatment of granuloma faciale
by: Alan Wong, DO, et al.
Published: (2023)

Efficacy of topical ruxolitinib for cutaneous dermatomyositis
by: Aviya Lanis, MD, et al.
Published: (2024)

Repigmentation in a patient with vitiligo on crisaborole 2% ointment
by: Idy Tam, MS, et al.
Published: (2021)

Correction to: Real-World Treatment Patterns in Patients with Vitiligo in the United States
by: David Rosmarin, et al.
Published: (2023)

Delayed granulomatous eruption of the nose associated with ruxolitinib
by: Margaret Brown, MD, et al.
Published: (2020)

Ruxolitinib for the treatment of myelofibrosis: its clinical potential
by: Ostojic A, et al.
Published: (2012)

Ruxolitinib cream monotherapy demonstrates rapid improvement in the extent and signs of mild to moderate atopic dermatitis across head and neck and other anatomic regions in adolescents and adults: pooled results from 2 phase 3 studies
by: Eric L. Simpson, et al.
Published: (2024)

Efficacy and Safety of 0.05% Halometasone/1% Triclosan Cream Versus 0.1% Mometasone Furoate Cream in the Treatment of truncal vitiligo: A Retrospective Study
by: Shu-Zhen Qi, et al.
Published: (2021)

Topical ruxolitinib in the treatment of refractory facial seborrheic dermatitis
by: Eleanor Pope, BA, et al.
Published: (2022)

Development of sebaceous carcinoma in a patient on ruxolitinib therapy
by: Noreen Mohsin, BS, et al.
Published: (2022)

Recalcitrant lichen planus pigmentosus treated with topical ruxolitinib
by: Hannah L. Cornman, BS, et al.
Published: (2023)

Designing a Topical Nanoliposomal Formulation of Ruxolitinib Phosphate
by: Atefeh Naeimifar, et al.
Published: (2023)

Diagnosed Prevalence and Incidence of Vitiligo in the United States: Analysis of Employer-Sponsored Insurance Claims
by: Markqayne Ray, et al.
Published: (2023)

Monobenzyl ether of hydroquinone 20 and 40% cream in depigmentation of patients with vitiligo: a randomized controlled trial
by: Medhat El Mofty, et al.
Published: (2020)

Healthcare Resource Use and Costs Among Individuals with Vitiligo and Psychosocial Comorbidities: Retrospective Analysis of an Insured US Population
by: Lofland JH, et al.
Published: (2024)

Successful treatment of alopecia totalis with ruxolitinib in a preadolescent patient
by: Danielle M. Peterson, MD, et al.
Published: (2020)

Tattoo pruritus successfully treated with ruxolitinib: A case series
by: Julianna Shin, BS, et al.
Published: (2024)